1. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era
   Gary H. Lyman et al, 2021, Frontiers in Oncology CrossRef
2. Cancer-Related Fatigue
   Lynn H. Gerber, 2017, Physical Medicine and Rehabilitation Clinics of North America CrossRef
3. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
   Matti Aapro et al, 2019, Frontiers in Pharmacology CrossRef
4. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis
   null null et al, 2022, Cochrane Database of Systematic Reviews CrossRef
5. Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices
   Lowell Hart et al, 2023, Cancer Medicine CrossRef
6. Erythropoiesis and chronic kidney disease–related anemia: From physiology to new therapeutic advancements
   Valeria Cernaro et al, 2019, Medicinal Research Reviews CrossRef
7. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
   Jared Weiss et al, 2021, Clinical Lung Cancer CrossRef
8. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER‐medicare study
   Robert S. Epstein et al, 2022, Cancer Treatment and Research Communications CrossRef